Literature DB >> 7682961

Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus.

S Zini1, M P Roisin, U Langel, T Bartfai, Y Ben-Ari.   

Abstract

Galanin is a 29-amino acid peptide widely distributed in the central nervous system where it modulates the release of several neurotransmitters and neurohormones. Because previous data had postulated that galanin could inhibit the release of excitatory amino acids and protect hippocampal neurons against anoxia, we have investigated the effect of galanin on the release of endogenous glutamate and aspartate evoked by potassium depolarization in rat hippocampal slices. Galanin, added to a concentration of 0.3 microM, produced a 50-60% reduction in the release of endogenous glutamate and aspartate as evoked by 40 mM K+. This effect was concentration-dependent with half-maximal effective galanin concentrations (EC50) of 1.7 and 5.9 nM for glutamate and aspartate, respectively. Such an effect was found to occur preferentially in the ventral rather than in the dorsal region of the hippocampus. The inhibitory effect of galanin on the K(+)-evoked release of excitatory amino acids was reversed by the specific galanin antagonist M-15 (0.3 microM), and by the ATP-sensitive potassium channel blocker glibenclamide (10 microM). Furthermore, M-15 alone increased the basal and the K(+)-evoked release of glutamate and aspartate from hippocampal slices. It is concluded that galanin exerts a tonic inhibition of excitatory glutamate/aspartate neurotransmission in the rat ventral hippocampus. The efficacy of glibenclamide in antagonizing the effect of galanin suggests the involvement of ATP-sensitive or -insensitive potassium channels in such a regulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682961     DOI: 10.1016/0922-4106(93)90162-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  37 in total

1.  Modulation of hippocampal excitability and seizures by galanin.

Authors:  A M Mazarati; J G Hohmann; A Bacon; H Liu; R Sankar; R A Steiner; D Wynick; C G Wasterlain
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 2.  Gene therapy for epilepsy.

Authors:  David W McCandless; Jeffrey W McCandless
Journal:  Metab Brain Dis       Date:  2010-09-23       Impact factor: 3.584

3.  Gene therapy in epilepsy.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

4.  A promising genetic approach for the treatment of epilepsy.

Authors:  Robyn Wallace
Journal:  Epilepsy Curr       Date:  2004 Jul-Aug       Impact factor: 7.500

5.  The role of the neuropeptide galanin in forming type-specific behavioral characteristics.

Authors:  V I Lyudyno; I N Abdurasulova; V M Klimenko
Journal:  Neurosci Behav Physiol       Date:  2008-01

6.  ATP-sensitive K+ channels are functional in expiratory neurones of normoxic cats.

Authors:  O Pierrefiche; A M Bischoff; D W Richter
Journal:  J Physiol       Date:  1996-07-15       Impact factor: 5.182

7.  Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus.

Authors:  G A Kinney; P J Emmerson; R J Miller
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

8.  Fronto-temporal galanin modulates impulse control.

Authors:  F Messanvi; A Perkins; J du Hoffmann; Y Chudasama
Journal:  Psychopharmacology (Berl)       Date:  2019-11-08       Impact factor: 4.530

9.  Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.

Authors:  A M Mazarati; H Liu; U Soomets; R Sankar; D Shin; H Katsumori; U Langel; C G Wasterlain
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice.

Authors:  Jefferson W Kinney; Grzegorz Starosta; Andrew Holmes; Craige C Wrenn; Rebecca J Yang; Ashley P Harris; Katharine C Long; Jacqueline N Crawley
Journal:  Learn Mem       Date:  2002 Jul-Aug       Impact factor: 2.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.